Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim¹, Tae Min Kim², Seok-Goo Cho³, Isidro Jarque⁴, Elżbieta Iskierka-Jażdżewska⁵, Li Mei Poon⁶, H Miles Prince⁷, Huilai Zhang⁸, Junning Cao⁹, Mingzhi Zhang¹⁰, Benoît Tessoulin¹¹, Sung Yong Oh¹², Francesca Lim¹³, Cecilia Carpio¹⁴, Tran-Der Tan¹⁵, Sabarish Ayyappan¹⁶, Antonio Gutierrez¹⁷, Jingxian Cai¹⁸, Melanie Ufkin¹⁸, Saleem Shariff¹⁹, Jurriaan Brouwer-Visser¹⁸, Aafia Chaudhry¹⁸, Hesham Mohamed¹⁸, Srikanth Ambati¹⁸, Jan Walewski²⁰; ELM-2 Investigators

Collaborators, Affiliations

Collaborators

ELM-2 Investigators:
Hannah Rose, Geoffrey Chong, Vinod Ganju, Michael Chu, Mary-Margaret Keating, Yuqin Song, Jun Zhu, Xiaoyan Ke, Shuhua Yi, Huilai Zhang, Qingyuan Zhang, Liqun Zou, Mingzhi Zhang, Dengju Li, Wenbin Qian, Ou Bai, Li Gao, Jie Jin, Caixia Li, Huiqiang Huang, Zheng Wei, Youhua Chen, Pengcheng He, Gandhi Laurent Damaj, Kamal Bouabdballah, Emmanuel Bachy, Corinne Haioun, Franck Morschhauser, Sylvain Choquet, Vincent Delwail, Catherine Thieblemont, Johannes Duell, Thomas Weber, Paul Graf La Rosee, Holger Hebart, Enrico Capochiani, Vittorio Zilioli, Francesca Rossi, Stefano Luminari, Pier Luigi Zinzani, Laura Bagnato, Gianluca Gaidano, Marco Brociner, Cristina Skert, Monica Tani, Roberta Battistini, Leonardo Flenghi, Ryusuke Yamamoto, Kunihiro Tsukasaki, Kenichi Ishizawa, Tomomi Tobai, Toshiki Uchida, Yosuke Minami, Nobuhiko Yamauchi, Junichiro Yuda, Masahiro Takeuchi, Hirokazu Nagai, Youko Suehiro, Yoshiaki Ogawa, Junya Kuroda, Tatsuro Jo, Hirohisa Nakamae, Isao Yoshida, Michal Taszner, Ewa Lech-Maranda, Wanda Knopinska-Posluszny, Tomasz Wrobel, Tadeusz Robak, Wen Son Hsieh, Shin Yeu Ong, Hyeon-Seok Eom, Yeung-Chul Mun, Young Rok Do, Jin Seok Kim, Byung Soo Kim, Jae-Cheol Jo, Ana Jimenez-Ubieto, Rafael Andreu, Alejandro Martin, Agustin Penedo Coello, Raul Cordoba, Aranzazu Alonso, Laura Magnano, Eva Gonzalez-Barca, Sara Miqueleiz, Tsai Yun Chen, Su Peng Yeh, Shang-Ju Wu, Ming-Chung Wang, David Cunningham, Andrea Kuhnl, David Tucker, David Lewis, Nagah Elmusharaf, John Allan, Thomas Jandl, Sami Ibrahimi, Deepa Jagadeesh, Lori Leslie, Parameswaran Venugopal, Jon Arnason, Jose C Villasboas, Rakhee Vaidya, Don Stevens, Farrukh Awan, Andreas Klein, Umar Farooq

Affiliations

¹ Sungkyunkwan University School of Medicine, Samsung Medical Center Division of Hematology-Oncology, Seoul, South Korea. wskimsmc@gmail.com.
² Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.
³ Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
⁴ Hematology Department, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer-CIBERONC, Valencia, Spain.
⁵ Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland.
⁶ Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore.
⁷ Epworth HealthCare and University of Melbourne, Melbourne, Victoria, Australia.
⁸ Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
⁹ Fudan University Shanghai Cancer Center, Shanghai, China.
¹⁰ Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
¹¹ Hematology Department, Nantes University Hospital, Nantes, France.
¹² Dong-A University Hospital, Busan, South Korea.
¹³ Singapore General Hospital, Singapore, Singapore.
¹⁴ Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain.
¹⁵ Hematology and Medical Oncology, Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan.
¹⁶ University of Iowa Hospital and Clinics, Iowa City, IA, USA.
¹⁷ Department of Hematology, Hospital Universitario Son Espases, IdISBa, Palma, Spain.
¹⁸ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
¹⁹ Regeneron UK, Ltd., Uxbridge, UK.
²⁰ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland.

PMID: 40240622
PMCID: PMC12122359
DOI: 10.1038/s43018-025-00967-6

Published Erratum

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim et al. Nat Cancer. 2025 May.

. 2025 May;6(5):907.

doi: 10.1038/s43018-025-00967-6.

Authors

Collaborators

ELM-2 Investigators:
Hannah Rose, Geoffrey Chong, Vinod Ganju, Michael Chu, Mary-Margaret Keating, Yuqin Song, Jun Zhu, Xiaoyan Ke, Shuhua Yi, Huilai Zhang, Qingyuan Zhang, Liqun Zou, Mingzhi Zhang, Dengju Li, Wenbin Qian, Ou Bai, Li Gao, Jie Jin, Caixia Li, Huiqiang Huang, Zheng Wei, Youhua Chen, Pengcheng He, Gandhi Laurent Damaj, Kamal Bouabdballah, Emmanuel Bachy, Corinne Haioun, Franck Morschhauser, Sylvain Choquet, Vincent Delwail, Catherine Thieblemont, Johannes Duell, Thomas Weber, Paul Graf La Rosee, Holger Hebart, Enrico Capochiani, Vittorio Zilioli, Francesca Rossi, Stefano Luminari, Pier Luigi Zinzani, Laura Bagnato, Gianluca Gaidano, Marco Brociner, Cristina Skert, Monica Tani, Roberta Battistini, Leonardo Flenghi, Ryusuke Yamamoto, Kunihiro Tsukasaki, Kenichi Ishizawa, Tomomi Tobai, Toshiki Uchida, Yosuke Minami, Nobuhiko Yamauchi, Junichiro Yuda, Masahiro Takeuchi, Hirokazu Nagai, Youko Suehiro, Yoshiaki Ogawa, Junya Kuroda, Tatsuro Jo, Hirohisa Nakamae, Isao Yoshida, Michal Taszner, Ewa Lech-Maranda, Wanda Knopinska-Posluszny, Tomasz Wrobel, Tadeusz Robak, Wen Son Hsieh, Shin Yeu Ong, Hyeon-Seok Eom, Yeung-Chul Mun, Young Rok Do, Jin Seok Kim, Byung Soo Kim, Jae-Cheol Jo, Ana Jimenez-Ubieto, Rafael Andreu, Alejandro Martin, Agustin Penedo Coello, Raul Cordoba, Aranzazu Alonso, Laura Magnano, Eva Gonzalez-Barca, Sara Miqueleiz, Tsai Yun Chen, Su Peng Yeh, Shang-Ju Wu, Ming-Chung Wang, David Cunningham, Andrea Kuhnl, David Tucker, David Lewis, Nagah Elmusharaf, John Allan, Thomas Jandl, Sami Ibrahimi, Deepa Jagadeesh, Lori Leslie, Parameswaran Venugopal, Jon Arnason, Jose C Villasboas, Rakhee Vaidya, Don Stevens, Farrukh Awan, Andreas Klein, Umar Farooq

Affiliations

¹ Sungkyunkwan University School of Medicine, Samsung Medical Center Division of Hematology-Oncology, Seoul, South Korea. wskimsmc@gmail.com.
² Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.
³ Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
⁴ Hematology Department, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer-CIBERONC, Valencia, Spain.
⁵ Copernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland.
⁶ Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore.
⁷ Epworth HealthCare and University of Melbourne, Melbourne, Victoria, Australia.
⁸ Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
⁹ Fudan University Shanghai Cancer Center, Shanghai, China.
¹⁰ Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
¹¹ Hematology Department, Nantes University Hospital, Nantes, France.
¹² Dong-A University Hospital, Busan, South Korea.
¹³ Singapore General Hospital, Singapore, Singapore.
¹⁴ Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain.
¹⁵ Hematology and Medical Oncology, Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan.
¹⁶ University of Iowa Hospital and Clinics, Iowa City, IA, USA.
¹⁷ Department of Hematology, Hospital Universitario Son Espases, IdISBa, Palma, Spain.
¹⁸ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
¹⁹ Regeneron UK, Ltd., Uxbridge, UK.
²⁰ Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland.

PMID: 40240622
PMCID: PMC12122359
DOI: 10.1038/s43018-025-00967-6

No abstract available

PubMed Disclaimer

Erratum for

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Collaborators

Affiliations

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Authors

Collaborators

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources